Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.900
+0.020 (1.06%)
At close: Apr 28, 2026, 4:00 PM EDT
1.900
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Acrivon Therapeutics Employees
As of December 31, 2025, Acrivon Therapeutics had 76 total employees, including 74 full-time and 2 part-time employees. The number of employees decreased by 2 or -2.56% compared to the previous year.
Employees
76
Change (1Y)
-2
Growth (1Y)
-2.56%
Revenue / Employee
n/a
Profits / Employee
-$1,025,066
Market Cap
73.61M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 76 | -2 | -2.56% |
| Dec 31, 2024 | 78 | 17 | 27.87% |
| Dec 31, 2023 | 61 | 17 | 38.64% |
| Dec 31, 2022 | 44 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 142 |
| Pelthos Therapeutics | 92 |
| XBiotech | 85 |
| Fortress Biotech | 78 |
| ImmuCell | 73 |
| aTyr Pharma | 60 |
| PMV Pharmaceuticals | 54 |
| Pliant Therapeutics | 49 |
ACRV News
- 11 days ago - Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities - GlobeNewsWire
- 13 days ago - Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 weeks ago - Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors - GlobeNewsWire
- 2 months ago - Acrivon Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Acrivon Therapeutics Transcript: European Society of Gynecological Oncology (ESGO) Congress 2026 - Transcripts
- 2 months ago - Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress - GlobeNewsWire